Ann: Voluntary Suspension, page-263

Hi @dr.biohacker

You raise some good points thank you...
The obvious and winning advantages are faster and far more accurate than an experienced professional even when they order max tests ie X-ray,bloods etc.....what other FDA approved apps do that??
Very small number of FDA approved apps btw.

Fast treatment of any illness for a vastly reduced cost is the goal of any new product in this sector.

No doubt the age of smartphone diagnosis has started and can't be stopped, the biggest market by far is Telehealth maybe not in this country as Australia is almost always last in any revolution.

Why will RAP be successful??
Simple answer is the size of the market world wide...
Over 35% of consultations are for respiratory illness, since sticking a stethoscope out of a monitor is out of the question, only one option will remain.
No competitors in this area means fast uptake, secondly using the USA as an example, three very large company's have millions of calls a year...
Why would one company say goodbye to over 35% of their business when the competitors sign a non exclusive agreement and they don't??
So it makes good business sense to sign up to smartcoughdx asap...

The product will not be available to the public in the medium term, its only to be used in conjunction with a visit to the GP, ED or Telehealth...it's another tool in the toolbox to make a fast, accurate diagnosis.

Good luck to you to....the days under 30 have gone forever..